Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4year (y) follow-up (FU) of CheckMate 649

被引：0

作者：

Wyrwicz, L. S. ^{[1
]}

Shitara, K. ^{[2
]}

Moehler, M. ^{[3
]}

Ajani, J. A. ^{[4
]}

Shen, L. ^{[5
]}

Garrido, M. ^{[6
]}

Gallardo Araneda, C. E. ^{[7
]}

Yamaguchi, K. ^{[8
]}

Cleary, J. ^{[9
]}

Elimova, E. ^{[10
]}

Bruges Maya, R. ^{[11
]}

Karamouzis, M. V. ^{[12
]}

Skoczylas, T. ^{[13
]}

Bragagnoli, A. C. ^{[14
]}

Liu, T. ^{[15
]}

Tehfe, M. ^{[16
]}

Feeney, K. ^{[17
,18
]}

Wang, R. ^{[19
]}

Zhang, J. ^{[20
]}

Janjigian, Y. Y. ^{[21
,22
]}

机构：

[1] Narodowy Instytut Onkol, Dept Radiotherapy & Oncol, Klin Onkol & Radioterapii, Warsaw, Poland

[2] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[3] Johannes Gutenberg Univ Clin, Dept Med, Mainz, Germany

[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[5] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res Minist Educ, Dept Gastrointestinal Oncol, Beijing, Peoples R China

[6] Pontificia Univ Catolica, Hematooncol Dept, Clin San Carlos de Apoquindo, Santiago, Chile

[7] Fdn Arturo Lopez Perez, Dept Med Oncol, Providencia, Chile

[8] Canc Inst Hosp JFCR, Gastroenterol Chemotherapy Dept, Koto Ku, Tokyo, Japan

[9] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[10] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

[11] Inst Nacl Cancerol ESE, Oncol Clin, Bogota, Colombia

[12] Laiko Gen Hosp Athens, Dept Biol Chem, Athens, Greece

[13] Med Univ Lublin, Dept Gen Surg, Klin Chirurg Ogolnej Gastroenterologicznej & No 2, Lublin, Poland

[14] Fundacao Pio Xii Hosp Canc Barretos, GI Canc, Barretos, Brazil

[15] Fudan Univ, Zhongshan Hosp, Oncol Dept, Shanghai, Peoples R China

[16] Ctr Hosp Univ Montreal, Oncol Ctr, Hematooncol Dept, Montreal, PQ, Canada

[17] Notre Dame Univ, Dept Canc Serv, Murdoch, WA, Australia

[18] Edith Cowan Univ, Murdoch, WA, Australia

[19] Bristol Myers Squibb, Oncol Precis Med, Princeton, NJ USA

[20] Bristol Myers Squibb, Oncol Clin Dev, Princeton, NJ USA

[21] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[22] Weill Cornell Med Coll, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.333

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

419P

引用

页码：S169 / S170

页数：2

共 50 条

[1] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649
Elimova, Elena
Shitara, Kohei
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan S.
Yamaguchi, Kensei
Cleary, James M.
Maya, Ricardo Elias Bruges
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Feeney, Kynan
Wang, Rui
Nathani, Raheel
Janjigian, Yelena Y.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses
Lei, Ming
Janjigian, Yelena Y.
Ajani, Jaffer A.
Moehler, Markus
Wang, Xuya
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Li, Mingshun
Poulart, Valerie
Wang, Yu
Doshi, Parul
Shitara., Kohei
CANCER RESEARCH, 2022, 82 (12)
[3] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
Shitara, Kohei
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan S.
Yamaguchi, Kensei
Cleary, James M.
Elimova, Elena
Maya, Ricardo Elias Bruges
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Feeney, Kynan
Wang, Rui
Nathani, Raheel
Janjigian, Yelena Y.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 306 - 306
[4] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
Moehler, M.
Janjigian, Y. Y.
Shitara, K.
Garrido, M.
Gallardo, C.
Shen, L.
Yamaguchi, K.
Wyrwicz, L.
Skoczylas, T.
Bragagnoli, A.
Liu, T.
Tehfe, M.
Elimova, E.
Bruges, R.
Cleary, J. M.
Karamouzis, M.
Soleymani, S.
Lei, M.
Amaya, Chanaga C.
Ajani, J. A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 114 - 115
[5] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
Janjigian, Yelena Y.
Shitara, Kohei
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Maya, Ricardo Elias Bruges
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Amaya-Chanaga, Carlos
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
Janjigian, Yelena Y.
Shitara, Kohei
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Maya, Ricardo Elias Bruges
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Amaya-Chanaga, Carlos
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 291 - 291
[7] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate
Moehler, Markus
Janjigian, Yelena Y.
Shitara, Kohei
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Bruges, Ricardo
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Chanaga, Carlos Amaya
Ajani, Jaffer A.
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 64 - 64
[8] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.
Janjigian, Yelena Y.
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Cleary, James M.
Elimova, Elena
Bruges, Ricardo Elias
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
McCraith, Stephen
Hu, Nan
Zhang, Jennifer
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 398 - 398
[9] Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
Janjigian, Y. Y.
Ajani, J. A.
Moehler, M.
Garrido, M.
Gallardo, C.
Shen, L.
Yamaguchi, K.
Wyrwicz, L.
Skoczylas, T.
Bragagnoli, A.
Liu, T.
Tehfe, M.
Elimova, E.
Li, M.
Poulart, V.
Lei, M.
Kondo, K.
Shitara, K.
ANNALS OF ONCOLOGY, 2021, 32 : S1329 - S1330
[10] Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
Moehler, M.
Shitara, K.
Garrido, M.
Salman, P.
Shen, L.
Wyrwicz, L.
Yamaguchi, K.
Skoczylas, T.
Campos Bragagnoli, A.
Liu, T.
Schenker, M.
Yanez, P.
Tehfe, M.
Poulart, V.
Cullen, D.
Lei, M.
Kondo, K.
Li, M.
Ajani, J. A.
Janjigian, Y. Y.
ANNALS OF ONCOLOGY, 2020, 31 : S1191 - S1191

← 1 2 3 4 5 →